Parameter control method, device and equipment of ophthalmic optical equipment and storage medium

By assessing eye data, identifying target risk stages, and using multi-channel irradiation parameters to control light source output, the system addresses post-laser refractive surgery visual quality issues and the combined prevention of presbyopia and AMD, achieving improved visual quality and safe light output.

CN123059291APending Publication Date: 2026-11-10BEIJING AIRDOC TECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611109367.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-24
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Some patients experience visual quality problems after laser refractive surgery, such as glare, halo, decreased contrast sensitivity, and dry eye. Presbyopia and age-related macular degeneration (AMD) often coexist, and existing equipment needs to be used separately, which increases the burden and cost.

Method used

By assessing visual quality or target risk using eye data, determining the target risk stage, acquiring multi-channel illumination parameters, controlling the light source for illumination output, and matching the multi-channel illumination parameters with eye data, visual quality can be improved or the risk of presbyopia and AMD can be reduced.

Benefits of technology

It effectively improves postoperative visual quality, prevents presbyopia and AMD, ensures the safety of light output, promotes corneal healing, improves tear film function and nerve regeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123059291A_ABST
    Figure CN123059291A_ABST
Patent Text Reader

Abstract

This application discloses a method, apparatus, device, and storage medium for parameter control of ophthalmic optical equipment. The method includes: performing visual quality assessment or target risk assessment on ocular data to obtain assessment results, wherein the target risks include presbyopia and AMD; determining the target risk stage corresponding to the ocular data based on the assessment results; acquiring multi-channel illumination parameters corresponding to the target risk stage, wherein the multi-channel illumination parameters are light source parameters for at least one channel used to improve post-refractive surgery visual quality or reduce the target risk; and controlling the light source to output light through at least one channel according to the multi-channel illumination parameters. This application can effectively improve visual quality or effectively prevent presbyopia and AMD in combination, and can ensure the safety of light output.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application belongs to the field of ophthalmic equipment control technology, specifically relating to a parameter control method, device, equipment, and storage medium for ophthalmic optical equipment. Background Technology

[0002] Laser refractive surgery (LASIK, SMILE, PRK, etc.) is the mainstream surgical method for correcting myopia, hyperopia, and astigmatism, with more than one million people undergoing the procedure worldwide each year. Despite the increasingly mature technology, some patients still experience visual quality problems after surgery, such as glare, halo, decreased contrast sensitivity, and dry eye.

[0003] Presbyopia and age-related macular degeneration (AMD) are two of the most common age-related eye diseases. Presbyopia affects almost all adults over 40, while AMD is the leading cause of blindness in people over 65. Presbyopia and AMD often coexist in the same patient (coexistence rate >40% in people over 60), but patients need to use different devices, increasing the burden and cost.

[0004] Therefore, how to improve postoperative visual quality or jointly prevent presbyopia and AMD using ophthalmic optical equipment, while ensuring safety in the process, is a technical problem that needs to be solved. Summary of the Invention

[0005] The purpose of this application is to provide a parameter control method, device, equipment, and storage medium for ophthalmic optical devices, which can improve postoperative visual quality or prevent presbyopia and AMD, while ensuring safety in the process.

[0006] To solve the above-mentioned technical problems, this application is implemented as follows: In a first aspect, embodiments of this application provide a parameter control method for ophthalmic optical devices, the method comprising: Visual quality assessment or target risk assessment is performed on ocular data to obtain assessment results, wherein the target risks include presbyopia and AMD; Based on the assessment results, the target risk stage corresponding to the eye data is determined; Obtain multi-channel illumination parameters corresponding to the target risk stage, wherein the multi-channel illumination parameters are light source parameters of at least one channel used to improve post-refractive visual quality or reduce the target risk; The light source is controlled to output light through at least one channel according to the multi-channel illumination parameters.

[0007] Secondly, embodiments of this application provide a parameter control device for ophthalmic optical equipment, comprising: The assessment module is used to perform visual quality assessment or target risk assessment on ocular data to obtain assessment results, wherein the target risks include presbyopia and AMD; The risk stage determination module is used to determine the target risk stage corresponding to the eye data based on the assessment results. The irradiation parameter acquisition module is used to acquire multi-channel irradiation parameters corresponding to the target risk stage. The multi-channel irradiation parameters are light source parameters of at least one channel used to improve postoperative visual quality or reduce target risk. The light source control module is used to control the light source to output light through at least one channel according to the multi-channel illumination parameters.

[0008] Thirdly, embodiments of this application provide an electronic device including a processor, a memory, and a program or instructions stored in the memory and executable on the processor, wherein the program or instructions, when executed by the processor, implement the steps of the method described in the first aspect.

[0009] Fourthly, embodiments of this application provide a readable storage medium on which a program or instructions are stored, which, when executed by a processor, implement the steps of the method described in the first aspect.

[0010] Fifthly, embodiments of this application provide a chip, the chip including a processor and a communication interface, the communication interface being coupled to the processor, the processor being used to run programs or instructions to implement the method as described in the first aspect.

[0011] In this embodiment, visual quality assessment or target risk assessment is performed on eye data to obtain assessment results. Based on the assessment results, the target risk stage corresponding to the eye data is determined. Multi-channel illumination parameters corresponding to the target risk stage are obtained. The light source is controlled to output light through at least one channel according to the multi-channel illumination parameters. In this way, the target risk stage corresponding to the eye data is determined by performing visual quality assessment or target risk assessment, and the light source is controlled to output light using the multi-channel illumination parameters corresponding to the target risk stage. The multi-channel illumination parameters used are matched with the eye data, which can effectively improve visual quality or effectively prevent presbyopia and AMD, and can ensure the safety of light output. Attached Figure Description

[0012] Figure 1 This is a flowchart of a parameter control method for an ophthalmic optical device provided in an embodiment of this application; Figure 2 This is a flowchart of another parameter control method for ophthalmic optical devices provided in the embodiments of this application; Figure 3This is a flowchart of another parameter control method for ophthalmic optical devices provided in the embodiments of this application; Figure 4 This is a schematic diagram of the structure of a parameter control device for an ophthalmic optical device provided in an embodiment of this application; Figure 5 A schematic diagram of the hardware structure of an electronic device to implement an embodiment of this application. Detailed Implementation

[0013] The technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, not all embodiments. Based on the embodiments of this application, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this application.

[0014] The terms "first," "second," etc., used in the specification and claims of this application are used to distinguish similar objects and not to describe a specific order or sequence. It should be understood that such use of data can be interchanged where appropriate so that embodiments of this application can be implemented in orders other than those illustrated or described herein. Furthermore, in the specification and claims, "and / or" indicates at least one of the connected objects, and the character " / " generally indicates that the preceding and following objects are in an "or" relationship.

[0015] The parameter control method, apparatus, device, and storage medium of the ophthalmic optical equipment provided in this application will be described in detail below with reference to the accompanying drawings and through specific embodiments and application scenarios.

[0016] Figure 1 This is a flowchart illustrating a parameter control method for an ophthalmic optical device according to an embodiment of this application. This parameter control method for ophthalmic optical devices can be applied to electronic devices such as ophthalmic optical devices. Figure 1 As shown, the method may include steps 110 to 140.

[0017] Step 110: Perform visual quality assessment or target risk assessment on the eye data to obtain the assessment results. The target risks include presbyopia and AMD.

[0018] Visual quality assessment is used to evaluate users after refractive surgery. Targeted risk assessment is used to assess the risk of presbyopia and AMD in elderly users.

[0019] In some embodiments, visual quality assessment of ocular data may include visual acuity assessment, phase difference analysis, contrast sensitivity detection, glare / halo assessment, tear film function assessment, and corneal sensitivity assessment. After obtaining the results of these assessments, a comprehensive evaluation is performed to obtain the visual quality assessment result. Visual acuity assessment is used to obtain uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA). Phase difference analysis is used to measure wavefront aberration. Wavefront aberration refers to the deviation between the actual wavefront and the ideal unbiased wavefront, mainly used to study the monochromatic aberration effect of human spatial visual acuity. Contrast sensitivity detection is performed at different spatial frequencies. Contrast sensitivity is defined as the reciprocal of the contrast threshold that the visual system can perceive; a low contrast threshold indicates high contrast sensitivity and good visual function. At a certain spatial frequency, the visual system has a certain contrast sensitivity; conversely, at the same contrast, the visual system has a certain spatial frequency resolution. Glare / halo assessment can be performed using data obtained through standardized questionnaires. Tear film function assessment is used to obtain tear film break-up time (BUT) and Schfrmer test results. Tear film break-up time is the time interval between blinking and the appearance of the first dry spot on the tear film surface while the eye remains open; it is used to estimate tear film stability, including non-invasive tear film break-up time measured using a tear film microscope and tear film break-up time measured using fluorescein. The Schfrmer test examines whether the lacrimal gland's tear secretion is normal. Under normal circumstances, the lacrimal gland cannot be felt. The user looks downwards towards the nose, and the thumb of the opposite hand pulls the outer canthus of the upper eyelid as far outwards and upwards as possible. This exposes the lacrimal gland, which may be swollen due to inflammation or tumors, under the conjunctiva of the superior fornix of the outer canthus for easier examination. Corneal sensitivity assessment can be performed using a tactile meter.

[0020] In other embodiments, targeted risk assessments of ocular data include presbyopia assessment and AMD risk assessment. Presbyopia assessment may include accommodative amplitude measurement, near visual acuity testing, and lens opacity examination. The ocular data used include accommodative amplitude, near visual acuity test results, and lens opacity. Accommodative amplitude refers to the maximum accommodative power of the human eye, i.e., the difference in refractive power between the far and near points of fixation; it is primarily age-related and gradually decreases with age. AMD risk assessment may include: drusen detection on fundus images, RPE and photoreceptor layer assessment on optical coherence tomography (OCT) images, and identification of lipofuscin deposition through autofluorescence imaging. AMD risk assessment may also include genetic risk assessment to evaluate loci such as CFH and ARMS2. Fundus autofluorescence (FAF) is a non-invasive imaging technique that assesses the function and health of RPE and photoreceptor cells by detecting the metabolic state of lipofuscin in retinal pigment epithelial (RPE) cells. Lipofuscin is a metabolic product of RPE cells, and its abnormal accumulation can lead to cell damage and even apoptosis. Autofluorescence imaging (AF) captures the autofluorescence signal of lipofuscin, directly reflecting the metabolic activity and distribution of RPE cells. Normal retina exhibits uniform low to medium fluorescence, while diseased areas show high fluorescence (lipofuscin accumulation) or low fluorescence (RPE atrophy or absence).

[0021] Step 120: Based on the assessment results, determine the target risk stage corresponding to the eye data.

[0022] The correspondence between the assessment result range and the risk stage can be preset. After the assessment result is determined, the assessment result range in which the assessment result is located is determined, and the risk stage corresponding to the assessment result range is determined as the target risk stage corresponding to the eye data.

[0023] Step 130: Obtain multi-channel illumination parameters corresponding to the target risk stage. The multi-channel illumination parameters are light source parameters of at least one channel used to improve post-refractive visual quality or reduce target risk.

[0024] The mapping between risk stages and multi-channel irradiation parameters can be pre-defined. After determining the target risk stage, the corresponding multi-channel irradiation parameters can be retrieved from this mapping. Different channels are used to irradiate different locations of the eye.

[0025] Step 140: Control the light source to output light through at least one channel according to the multi-channel illumination parameters.

[0026] The light source can include a multi-channel illumination source, or an array of light sources to cover different channels. Based on multi-channel illumination parameters, the light source is controlled to output light through at least one channel to illuminate the eye, improving visual quality or reducing the risk of presbyopia and AMD.

[0027] The parameter control method for ophthalmic optical devices provided in this application involves performing visual quality assessment or target risk assessment on eye data to obtain assessment results. Based on the assessment results, the target risk stage corresponding to the eye data is determined. Multi-channel illumination parameters corresponding to the target risk stage are obtained, and the light source is controlled to output light through at least one channel according to the multi-channel illumination parameters. In this way, by performing visual quality assessment or target risk assessment to determine the target risk stage corresponding to the eye data, and using the multi-channel illumination parameters corresponding to the target risk stage to control the light source to output light, the multi-channel illumination parameters used are matched with the eye data, which can effectively improve visual quality or effectively prevent presbyopia and AMD, and can ensure the safety of light output.

[0028] Figure 2 This is a flowchart of another parameter control method for ophthalmic optical devices provided in this application embodiment. Based on the above embodiments, this embodiment mainly introduces the recovery of visual quality after refractive surgery. Figure 2 As shown, the method may include steps 210 to 240.

[0029] Step 210: Perform a target risk assessment on the eye data to obtain the assessment results.

[0030] In some embodiments of this application, the ocular data includes uncorrected visual acuity, best corrected visual acuity, wavefront aberration, contrast sensitivity, tear film breakup time, and Schirmer test results; The visual quality assessment or target risk assessment of the eye data yields assessment results, including: The visual quality score is obtained by weighting and summing the uncorrected visual acuity, best corrected visual acuity, wavefront aberration, contrast sensitivity, tear film breakup time, and Schirmer test results.

[0031] It can pre-enter the type of refractive surgery, the date of refractive surgery, and the pre-operative refractive power; perform UCVA and BCVA tests using the ETDRS digital visual acuity chart; record higher-order aberrations RMS using wavefront aberration measurement; obtain tear film breakup time and Schirmer test results through tear film assessment; and obtain contrast sensitivity through Cochet-Bonnet corneal perception testing.

[0032] The impact of different ocular data on visual quality recovery can be pre-assigned with appropriate weights. When assessing visual quality, the standardized uncorrected visual acuity, best corrected visual acuity, wavefront aberration, contrast sensitivity, tear film breakup time, and Schirmer test results are weighted and summed to form a visual quality score, which can be expressed as the following formula: VQI = 0.2×UCVA_norm + 0.15×BCVA_norm + 0.2×(1-HOA_RMS_norm) + 0.2×BUT_norm + 0.1×Schirmer_norm + 0.15× Sensitivity_norm Wherein, VQI represents visual quality score, UCVA_norm represents the standardized data of UCVA, BCVA_norm represents the standardized data of BCVA, HOA_RMS_norm represents the standardized data of wavefront aberration, BUT_norm represents the standardized data of BUT, Schirmer_norm represents the standardized data of Schirmer test results, and Sensitivity_norm represents the standardized data of contrast sensitivity.

[0033] Step 220: Determine the target risk stage based on the visual quality score and the number of days after refractive surgery.

[0034] The recovery of visual quality after refractive surgery is also related to the number of days after the surgery. In this case, the target risk stage can be determined by combining the visual quality score and the number of days after the surgery.

[0035] In some embodiments of this application, the target risk phase includes: an early healing phase, a mid-term reshaping phase, and a late optimization phase; The determination of the target risk phase based on the visual quality score and the number of days post-refractive surgery includes: If the number of days after refractive surgery is less than or equal to the first day threshold and the visual quality score is less than the first score threshold, the target risk stage is determined to be the early healing stage. If the number of days after refractive surgery is greater than the first day threshold and less than or equal to the second day threshold, and the visual quality score is less than the second score threshold, the target risk stage is determined to be the mid-term remodeling stage. If the number of days after refractive surgery is greater than the second day threshold and less than or equal to the third day threshold, the target risk stage is determined to be the late optimization stage; Wherein, the first score threshold is less than the second score threshold.

[0036] The early healing phase primarily promotes corneal epithelial healing, generally occurring 1-2 weeks after refractive surgery, with a first-day threshold of 14 days. The intermediate remodeling phase mainly focuses on maintaining tear film stability and stromal remodeling, typically requiring 2 to 4 weeks, with a second-day threshold of 28 or 42 days. The late optimization phase primarily improves corneal sensitivity and enhances visual quality, and can occur from the intermediate remodeling phase up to 12 weeks later, which can include 5-12 weeks or 7-12 weeks after refractive surgery, with a third-day threshold of 84 days.

[0037] A higher visual quality score indicates better visual quality. In the early healing stage, visual quality is generally poor, and the visual quality score is less than the first score threshold. In the mid-stage remodeling stage, visual quality improves, and the visual quality score is less than the second score threshold.

[0038] In some embodiments, the type of refractive surgery includes LASIK, PRK, or SMILE; The threshold for the first day corresponding to PRK is greater than the threshold for the first day corresponding to LASIK and SMILE; The second day threshold corresponding to PRK is greater than the second day threshold corresponding to LASIK and SMILE; The third day threshold corresponding to PRK is greater than the third day threshold corresponding to LASIK and SMILE.

[0039] Since PRK heals more slowly, the day threshold for PRK can be adjusted based on the day thresholds for LASIK and SMILE. The day threshold for PRK can be a target multiple of the day thresholds for LASIK and SMILE, and this target multiple is a number greater than 1, such as 1.5 times.

[0040] Step 230: Obtain multi-channel illumination parameters corresponding to the target risk stage, wherein the multi-channel illumination parameters are light source parameters of at least one channel used to improve postoperative visual quality of refractive surgery.

[0041] Multi-channel irradiation parameters can include the power density, irradiation duration, and frequency of the respective channels.

[0042] In some embodiments, the irradiation site of the corneal channel is the entire corneal surface, and the corneal channel uses 630-680nm red light; the irradiation site of the tear film channel is the meibomian gland region, and the tear film channel uses 630-680nm red light; the irradiation site of the nerve regeneration channel is the entire corneal surface, and the nerve regeneration channel uses 810-850nm near-infrared light. The corneal channel uses 630-680nm red light to promote corneal epithelial healing. The tear film channel uses 630-680nm red light to promote meibomian gland function and improve the lipid layer. The nerve regeneration channel uses 810-850nm near-infrared light to irradiate the deep layers of the entire corneal surface, promoting deep stromal remodeling and corneal nerve fiber regeneration.

[0043] In some embodiments, the power density corresponding to the corneal channel can be 8-30 mW / cm² (conservative corneal dose), with an irradiation duration of 2-3 minutes, which can begin 24-48 hours after refractive surgery. The power density corresponding to the tear film channel can be 15-35 mW / cm², with an irradiation duration of 2 minutes per eyelid. The power density corresponding to the neural regeneration channel can be 8-15 mW / cm², with an irradiation duration of 5 minutes. The power density range for all channels can be 8-50 mW / cm². In the early healing phase, corneal channel irradiation can be performed once daily at a power density of 15 mW / cm² for 2 minutes to promote epithelial healing; in the intermediate remodeling phase, corneal and tear film channels can be irradiated every other day to maintain tear film stability and stromal remodeling; in the late optimization phase, neural regeneration channels can be irradiated twice weekly to improve corneal sensitivity and enhance visual quality.

[0044] In other embodiments, the multi-channel irradiation parameters corresponding to each risk stage are as follows: Early healing stage: corneal channel power density is 10-15 mW / cm², irradiation duration is 120 s, tear film channel is not activated, nerve regeneration channel power density is 8-12 mW / cm², irradiation duration is 60 s; Intermediate remodeling stage: corneal channel power density is 15-25 mW / cm², irradiation duration is 150 s, tear film channel power density is 15-25 mW / cm², irradiation duration is 120 s per eyelid, nerve regeneration channel power density is 12-20 mW / cm², irradiation duration is 120 s; Late optimization stage: corneal channel power density is 20-30 mW / cm², irradiation duration is 120 s, tear film channel power density is 25-35 mW / cm², irradiation duration is 120 s per eyelid, nerve regeneration channel power density is 20-35 mW / cm². mW / cm², irradiation duration is 300s.

[0045] Step 240: Control the light source to output light through at least one channel according to the multi-channel illumination parameters.

[0046] The light source can include: a full-surface corneal red light array, a meibomian gland-targeted red light array, and a deep corneal near-infrared array. The full-surface corneal red light array corresponds to the corneal channel, with a peak wavelength of 660±5nm, an array configuration of 6×6 matrix, irradiating the entire corneal surface (12mm in diameter), and a power density of 8-30 mW / cm². The meibomian gland-targeted red light array corresponds to the tear film channel, with an array configuration of 2×4 linear arrays × 2 (one set for each of the upper and lower eyelids), a power density of 15-35 mW / cm², irradiating the upper and lower meibomian gland regions. The deep corneal near-infrared array corresponds to the nerve regeneration channel, with a peak wavelength of 830±10nm, an array configuration of 4×4 matrix, a power density of 8-50 mW / cm², irradiating the entire corneal surface for deep penetration.

[0047] Before controlling the light source to output light, the device can be aligned to locate and confirm the cornea and meibomian gland areas.

[0048] The parameter control method for ophthalmic optical devices provided in this application assesses visual quality data to obtain a visual quality score. Based on the visual quality score and the number of days post-refractive surgery, a target risk stage is determined. Multi-channel illumination parameters corresponding to the target risk stage are obtained, and the light source is controlled to output light through at least one channel according to the multi-channel illumination parameters. By jointly determining the target risk stage based on both the visual quality score and the number of days post-refractive surgery, the accuracy of target risk stage determination can be improved. Using corresponding multi-channel parameters for light output based on different stages post-refractive surgery is beneficial for the recovery of visual quality after refractive surgery. Furthermore, the matching of multi-channel illumination parameters with the target risk stage ensures the safety of light output.

[0049] Based on the above technical solution, the method may further include: acquiring corneal thickness, corneal temperature, and Scheimpflug image backscattering intensity during the process of controlling the light source to output light; determining the corneal response index based on the corneal thickness, corneal temperature, and Scheimpflug image backscattering intensity; and adjusting the multi-channel illumination parameters based on the corneal response index.

[0050] The corneal response index characterizes the cornea's sensitivity to light.

[0051] Ophthalmic optical devices may include a sensor module that integrates a Scheimpflug imaging camera (1280×960 pixels, 50 fps) and a corneal topography measurement ring with 22 Placido rings. During illumination output controlled by a light source, the sensor module acquires corneal thickness every 10 seconds via optical coherence ranging (axial resolution 5 μm). It also monitors corneal temperature using a non-contact infrared thermometer (accuracy ±0.1°C, sampling rate 2 Hz). If the corneal surface temperature exceeds a threshold (e.g., 37.5°C, an increase of more than 1.5°C from the baseline), the sensor module sends an alarm signal to the processing unit. The sensor module also acquires Scheimpflug images via the Scheimpflug imaging camera to determine the intensity of backscattering from the Scheimpflug images.

[0052] A first change in corneal thickness relative to a baseline corneal thickness can be determined, along with a first ratio of this first change to the baseline corneal thickness. A second change in corneal temperature relative to a baseline corneal temperature can be determined, along with a second ratio of this second change to the baseline corneal temperature. A third ratio of the Scheimpflug image backscattering intensity to the baseline Scheimpflug image backscattering intensity can be determined. The weighted sum of the first, second, and third ratios is then used as the corneal response index. The formula for calculating the corneal response index can be expressed as follows: CRI= 0.4 × (ΔCT / CT_baseline) + 0.3 × (ΔTemp / Temp_threshold) + 0.3× (scatter_coefficient / scatter_baseline) Wherein, CRI represents the corneal response index, ΔCT represents the first change in corneal thickness, CT_baseline represents the corneal thickness baseline, ΔTemp represents the second change in corneal temperature, Temp_threshold represents the corneal temperature baseline, scatter_coefficient represents the backscatter intensity of the Scheimpflug image, and scatter_baseline represents the backscatter intensity baseline of the Scheimpflug image.

[0053] In some embodiments of this application, adjusting the multi-channel irradiation parameters according to the corneal response index includes: reducing the power density in the multi-channel irradiation parameters by a first amount when the corneal response index is greater than a first threshold; and increasing the power density in the multi-channel irradiation parameters by a second amount when the corneal response index is less than a second threshold; wherein the first threshold is greater than the second threshold.

[0054] The first threshold can be 0.7, and the second threshold can be 0.3. The first amplitude can be 20%, and the second amplitude can be 10%. That is, when the corneal response index exceeds 0.7, the power density of each channel currently outputting light will be reduced by 20%. When the corneal response index is below 0.3, the power density of each channel currently outputting light will be increased by 10%, but not exceeding the maximum power density.

[0055] By adjusting the power density in the multi-channel illumination parameters based on the corneal response index, the safety of light output can be further ensured.

[0056] Optionally, the effect of light output can be evaluated at a certain time after refractive surgery, such as visual improvement assessment at 1 month, 3 months and 6 months after surgery; aberration change assessment to determine whether higher-order aberrations have been reduced; symptom scoring to determine the degree of improvement in glare and dry eye; and contrast sensitivity assessment to determine the degree of improvement in each spatial frequency.

[0057] Optionally, after the light output is performed, a comfort assessment can be conducted, data can be recorded, and suggestions for the next light output and follow-up time can be generated.

[0058] This application provides a phased light output scheme for postoperative users of LASIK, SMILE, PRK, etc.: Early stage (1-2 weeks) uses 660nm red light to promote epithelial healing; mid-stage (3-4 weeks) increases meibomian gland irradiation to improve tear film; late stage (5-12 weeks) uses near-infrared light to promote nerve regeneration. The power density range is 8-50mW / cm², and corneal irradiation uses a conservative dose of 8-30mW / cm². This application comprehensively improves postoperative visual quality by promoting corneal healing, improving tear film function, and promoting nerve regeneration.

[0059] Figure 3 This is a flowchart of another parameter control method for ophthalmic optical devices provided in this application embodiment. This embodiment... Figure 1 Based on the illustrated embodiments, this paper mainly introduces a combined prevention strategy for presbyopia and AMD. The at least one channel includes an AMD channel and a presbyopia channel. Presbyopia primarily involves the degeneration of lens and ciliary muscle function, while AMD primarily involves progressive damage to the retinal pigment epithelium and photoreceptors. The common pathological basis of both includes accumulated oxidative stress, decreased mitochondrial function, and chronic inflammation. Photobiological modulation has been shown to improve mitochondrial function, reduce oxidative stress, and regulate inflammatory responses. Using photobiological modulation for the combined prevention of presbyopia and AMD may simultaneously delay the progression of both diseases through shared cellular protective mechanisms.

[0060] like Figure 3 As shown, the method may include steps 310 to 340.

[0061] Step 310: Perform a target risk assessment on the eye data to obtain the assessment results. The target risks include presbyopia and AMD. The assessment results include the AMD risk score and the severity of presbyopia.

[0062] Ocular data can include the number of drusen, the area of ​​the drusen region, autofluorescence intensity score, genetic risk score, accommodative amplitude, and near-additional power. Patient information can be entered to obtain age, family history, and previous AMD / presbyopia records; the number and area of ​​drusen can be automatically determined based on fundus images; RPE layer assessment and fluid / CNV detection can be performed based on SS-OCT scanning; lipofuscin deposition score can be determined based on autofluorescence imaging; and accommodative function assessment can be performed to determine accommodative amplitude and near-additional power.

[0063] The number of drusen, the area of ​​the drusen region, the autofluorescence intensity score, and the genetic risk score were standardized. The standardized drusen number, drusen region area, autofluorescence intensity score, and genetic risk score were then weighted and summed to obtain the AMD risk score, which can be expressed as the following formula: AMD_score = 0.35×drusen_norm + 0.25×area_norm + 0.20×FAF_norm +0.20×genetic_risk Wherein, AMD_score represents the AMD risk score, drusen_norm represents the number of drusen after normalization, area_norm represents the area of ​​drusen after normalization, FAF_norm represents the autofluorescence intensity score after normalization, and genetic_risk represents the genetic risk score after normalization.

[0064] The severity of presbyopia can be determined based on the near-additional diopter, as shown below: presbyopia_severity = add_power / 3.0 Among them, presbyopia_severity represents the severity of presbyopia, and add_power represents the additional power.

[0065] Step 320: Determine the target risk stage based on the AMD risk score and the severity of presbyopia.

[0066] In some embodiments, multiple risk stages can be pre-defined, each corresponding to a specific AMD risk score range and a presbyopia severity range. A target risk stage is determined based on the determined AMD risk score range and the presbyopia severity range. The target risk stage can include a low-risk stage, a medium-risk stage, and a high-risk stage. A low-risk stage is characterized by the absence of AMD symptoms (AMD risk score below a first scoring threshold) and mild presbyopia (presbyopia severity less than a first severity threshold). A medium-risk stage is characterized by early AMD symptoms (AMD risk score greater than or equal to the first scoring threshold and less than a second scoring threshold) or moderate presbyopia (presbyopia severity greater than or equal to the first severity threshold and less than a first severity threshold). A high-risk stage is characterized by multiple drusen (AMD risk score greater than or equal to the second scoring threshold) or severe presbyopia (presbyopia severity greater than or equal to the first severity threshold).

[0067] In other embodiments, AMD risk stages can be pre-defined, with each AMD risk stage corresponding to a different AMD risk score range. Based on the determined AMD risk score, the AMD risk score range to which the AMD risk score falls is determined, and the AMD risk stage corresponding to the AMD risk score range is determined as the target risk stage. Optionally, the AMD risk stages may include a low-risk AMD stage, a medium-risk AMD stage, and a high-risk AMD stage. When the AMD risk score is less than a first score threshold (e.g., 0.3), the target risk stage is determined to be the low-risk AMD stage; when the AMD risk score is greater than or equal to the first score threshold (e.g., 0.3) and less than a second score threshold (e.g., 0.6), the target risk stage is determined to be the medium-risk AMD stage; and when the AMD risk score is greater than or equal to the second score threshold, the target risk stage is determined to be the high-risk AMD stage.

[0068] Step 330: Obtain the AMD channel irradiation parameters and presbyopia channel parameters corresponding to the target risk stage.

[0069] In some embodiments, for the low-risk stage (no signs of AMD, mild presbyopia), a preventative low-dose regimen can be used, with a power density of 10 mW / cm² and an irradiation duration of 2 minutes for the AMD channel (macula), and a power density of 15 mW / cm² and an irradiation duration of 3 minutes for the presbyopia channel (ciliary muscle); for the intermediate-risk stage (early signs of AMD or moderate presbyopia), a standard regimen can be used, with a power density of 15 mW / cm² and an irradiation duration of 3 minutes for the AMD channel (macula), and a power density of 25 mW / cm² and an irradiation duration of 4 minutes for the presbyopia channel (ciliary muscle); for the high-risk stage (multiple drusen or severe presbyopia), an enhanced regimen can be used, with a power density of 20 mW / cm² and an irradiation duration of 4 minutes for the AMD channel (macula), and a power density of 30 mW / cm² and an irradiation duration of 5 minutes for the presbyopia channel (ciliary muscle).

[0070] In other embodiments, different AMD risk stages can be pre-set with varying AMD channel irradiation parameters. For example, in the low-risk AMD stage, the AMD channel power density can be 10 mW / cm², and the irradiation duration is 120 s; in the medium-risk AMD stage, the AMD channel power density can be 15 mW / cm², and the irradiation duration is 180 s; in the high-risk AMD stage, the AMD channel power density can be 20 mW / cm², and the irradiation duration is 240 s. The presbyopia channel parameters are determined based on the severity of presbyopia, and the power density and irradiation duration of the presbyopia channel can be determined according to the following formula: P_presbyopia = 15 + 15 × presbyopia_severity t_presbyopia = 180 + 120 × presbyopia_severity Wherein, P_presbyopia represents the power density of the presbyopia channel, ranging from 15-30 mW / cm², presbyopia_severity represents the severity of presbyopia, and t_presbyopia represents the irradiation duration of the presbyopia channel, ranging from 180-300 s.

[0071] Step 340: Control the light source to output light through at least one channel according to the multi-channel illumination parameters.

[0072] The light source is controlled to output illumination according to the AMD channel illumination parameters, and the light source is also controlled to output illumination according to the presbyopia channel parameters. The frequency of illumination output can vary depending on the risk level; for example, it can be once daily for high-risk levels, and 3-5 times per week for medium- and low-risk levels.

[0073] In some embodiments, each channel can employ an array light source. For the AMD channel, the array configuration can be a 6×6 matrix, with the illumination area being a 10° region in the center of the macula (spot diameter ~5mm). For the presbyopia channel, the array configuration can be a 4×4 matrix, with the illumination area including the ciliary muscle annular region (inner diameter 8mm, outer diameter 20mm) and the central region of the lens. The spot switching method is motorized zoom, switching between the ciliary muscle annular region and the central region of the lens.

[0074] In some embodiments of this application, controlling the light source to output illumination for at least one channel according to the multi-channel illumination parameters includes: controlling the light source to output illumination for the AMD channel according to the AMD channel illumination parameters, and after the illumination output for the AMD channel is completed, controlling the light source to output illumination for the presbyopia channel according to the presbyopia channel parameters.

[0075] By first outputting light through the AMD channel and then outputting light through the presbyopia channel after the AMD channel output is complete, both AMD and presbyopia can be prevented together, thus improving the safety of light output.

[0076] The parameter control method for ophthalmic optical devices provided in this application assesses the risk of AMD and presbyopia based on eye data, obtaining an AMD risk score and the severity of presbyopia. Based on the AMD risk score and the severity of presbyopia, a target risk stage is determined. The corresponding AMD channel illumination parameters and presbyopia channel parameters are obtained, and the light source is controlled to output light for both the AMD and presbyopia channels according to these parameters. This method enables joint prevention of AMD and presbyopia. Furthermore, different target risk stages use corresponding AMD channel illumination parameters and presbyopia channel parameters for light output, and the multi-channel illumination parameters are matched with the target risk stage, ensuring the safety of the light output.

[0077] Based on the above technical solution, the method further includes: acquiring an optical coherence tomography (OCT) image during the illumination output of the AMD channel, and stopping the illumination output of the AMD channel when choroidal neovascularization is detected based on the OCT image.

[0078] During the illumination output of the AMD channel, optical coherence tomography (OCT) images can be acquired through the neovascularization detection OCT module. Choroidal neovascularization (CNV) can be detected on the OCT images. If choroidal neovascularization is detected, the illumination output of the AMD channel is stopped. Referral warnings can also be issued to ensure the safety of illumination output.

[0079] Through the embodiments of this application, the progression of presbyopia can be slowed down, the rate of increase in near-additional myopia can be reduced, the progression of AMD can be delayed, drusen can be stabilized or eliminated, visual function can be maintained, and contrast sensitivity and dark adaptation can be preserved.

[0080] Optional features include: tracking changes in the number and size of drusen as an indicator of AMD progression; and assessing the rate of increase in near-additional myopia as an indicator of presbyopia progression.

[0081] Optional safety monitoring can also be performed, including vision monitoring, fundus examination, AMD indicator monitoring, lens monitoring, and presbyopia progression monitoring. Vision monitoring can be performed by the user monthly. Fundus examination can be performed professionally every 3-6 months. Lens monitoring is used to monitor changes in opacity.

[0082] In this embodiment, a multi-target differentiated irradiation strategy is adopted to target the common risk factors of two age-related eye diseases: AMD prevention uses 630-680nm red light to irradiate the macula (8-25mW / cm², 3 minutes), and presbyopia prevention uses 810-850nm near-infrared light to irradiate the ciliary muscle and lens area (15-30mW / cm², 4 minutes), thus achieving joint prevention of AMD and presbyopia.

[0083] It should be noted that the parameter control method for ophthalmic optical devices provided in this application embodiment can be executed by a parameter control device for ophthalmic optical devices, or a control module within the parameter control device for executing the method of loading the parameter control device for ophthalmic optical devices. This application embodiment uses the execution of the parameter control method for loading the parameter control device for ophthalmic optical devices by a parameter control device as an example to illustrate the parameter control method for ophthalmic optical devices provided in this application embodiment.

[0084] Figure 4 This is a schematic diagram of the structure of a parameter control device for ophthalmic optical equipment provided in an embodiment of this application, as shown below. Figure 4 As shown, the parameter control device of this ophthalmic optical equipment includes: The assessment module 410 is used to perform visual quality assessment or target risk assessment on eye data to obtain assessment results, wherein the target risks include presbyopia and AMD. Risk stage determination module 420 is used to determine the target risk stage corresponding to the eye data based on the assessment results; The irradiation parameter acquisition module 430 is used to acquire multi-channel irradiation parameters corresponding to the target risk stage. The multi-channel irradiation parameters are light source parameters of at least one channel used to improve post-refractive visual quality or reduce target risk. The light source control module 440 is used to control the light source to output light through at least one channel according to the multi-channel illumination parameters.

[0085] Optionally, the evaluation results include a visual quality score, and the at least one channel includes a corneal channel, a tear film channel, and a neural regeneration channel; The risk stage determination module is specifically used for: The target risk phase is determined based on the visual quality score and the number of days after refractive surgery.

[0086] Optionally, the ocular data includes uncorrected visual acuity, best corrected visual acuity, wavefront aberration, contrast sensitivity, tear film breakup time, and Schirmer test results; The evaluation module is specifically used for: The visual quality score is obtained by weighting and summing the uncorrected visual acuity, best corrected visual acuity, wavefront aberration, contrast sensitivity, tear film breakup time, and Schirmer test results.

[0087] Optionally, the target risk phase includes: an early healing phase, a mid-term reshaping phase, and a late-term optimization phase; The risk stage determination module is specifically used for: If the number of days after refractive surgery is less than or equal to the first day threshold and the visual quality score is less than the first score threshold, the target risk stage is determined to be the early healing stage. If the number of days after refractive surgery is greater than the first day threshold and less than or equal to the second day threshold, and the visual quality score is less than the second score threshold, the target risk stage is determined to be the mid-term remodeling stage. If the number of days after refractive surgery is greater than the second day threshold and less than or equal to the third day threshold, the target risk stage is determined to be the late optimization stage; Wherein, the first score threshold is less than the second score threshold.

[0088] Optionally, the type of refractive surgery includes LASIK, PRK, or SMILE; The threshold for the first day corresponding to PRK is greater than the threshold for the first day corresponding to LASIK and SMILE; The second day threshold corresponding to PRK is greater than the second day threshold corresponding to LASIK and SMILE; The third day threshold corresponding to PRK is greater than the third day threshold corresponding to LASIK and SMILE.

[0089] Optionally, the irradiation location of the corneal channel is the entire surface of the cornea, and the corneal channel uses 630-680nm red light; The irradiation location of the tear film channel is the meibomian gland region, and the tear film channel uses 630-680nm red light; The irradiation site of the nerve regeneration channel is the entire surface of the cornea, and the nerve regeneration channel uses 810-850nm near-infrared light.

[0090] Optionally, the device further includes: The corneal response monitoring module is used to acquire corneal thickness, corneal temperature, and Scheimpflug image backscattering intensity during the process of controlling the light source to output light; determine the corneal response index based on the corneal thickness, corneal temperature, and Scheimpflug image backscattering intensity, and adjust the multi-channel illumination parameters based on the corneal response index.

[0091] Optionally, adjusting the multi-channel irradiation parameters according to the corneal response index includes: When the corneal response index is greater than a first threshold, the power density in the multi-channel irradiation parameters is reduced by a first amount; when the corneal response index is less than a second threshold, the power density in the multi-channel irradiation parameters is increased by a second amount; the first threshold is greater than the second threshold.

[0092] Optionally, the evaluation results include an AMD risk score and the severity of presbyopia; the at least one channel includes an AMD channel and a presbyopia channel; The risk stage determination module is specifically used for: The target risk stage is determined based on the AMD risk score and the severity of presbyopia. The irradiation parameter acquisition module is specifically used for: Obtain the AMD channel irradiation parameters and presbyopia channel parameters corresponding to the target risk stage.

[0093] Optionally, for the AMD channel, the irradiation area includes the central 10-degree region of the macula, using 630-680nm red light with a power density of 8-25 mW / cm². For the presbyopia channel, the irradiation area includes the ciliary muscle ring area and the central area of ​​the lens, using 810-850nm near-infrared light with a power density of 15-30 mW / cm².

[0094] Optionally, the light source control module is specifically used for: The light source is controlled to output illumination for the AMD channel according to the AMD channel illumination parameters, and after the illumination output for the AMD channel ends, the light source is controlled to output illumination for the presbyopia channel according to the presbyopia channel parameters.

[0095] Optionally, the device further includes: The neovascularization detection module is used to acquire optical coherence tomography (OCT) images during the illumination output of the AMD channel, and to stop the illumination output of the AMD channel when choroidal neovascularization is detected based on the OCT images.

[0096] The parameter control device for ophthalmic optical equipment in this application embodiment can be a device, or a component, integrated circuit, or chip in a terminal. The device can be a mobile electronic device or a non-mobile electronic device. For example, mobile electronic devices can be mobile phones, tablets, laptops, PDAs, in-vehicle electronic devices, wearable devices, ultra-mobile personal computers (UMPCs), netbooks, or personal digital assistants (PDAs), etc., while non-mobile electronic devices can be servers, network-attached storage (NAS), personal computers (PCs), televisions (TVs), ATMs, or self-service machines, etc. This application embodiment does not impose specific limitations.

[0097] The parameter control device for ophthalmic optical equipment in this application embodiment can be a device with an operating system. This operating system can be Android, iOS, or other possible operating systems; this application embodiment does not specifically limit the specific operating system used.

[0098] The parameter control device for ophthalmic optical equipment provided in this application embodiment can achieve… Figures 1 to 3 The various processes implemented in the method implementation examples will not be described again here to avoid repetition.

[0099] The parameter control device for ophthalmic optical equipment provided in this application provides an assessment result by performing visual quality assessment or target risk assessment on eye data. Based on the assessment result, the target risk stage corresponding to the eye data is determined, and multi-channel illumination parameters corresponding to the target risk stage are obtained. The light source is controlled to output light through at least one channel according to the multi-channel illumination parameters. In this way, by performing visual quality assessment or target risk assessment to determine the target risk stage corresponding to the eye data, and using the multi-channel illumination parameters corresponding to the target risk stage to control the light source to output light, the multi-channel illumination parameters used are matched with the eye data, which can effectively improve visual quality or effectively prevent presbyopia and AMD, and can ensure the safety of light output.

[0100] Optionally, embodiments of this application also provide an electronic device, including a processor, a memory, and a program or instructions stored in the memory and executable on the processor. When the program or instructions are executed by the processor, they implement the various processes of the above-described parameter control method embodiments for ophthalmic optical devices and achieve the same technical effects. To avoid repetition, they will not be described again here.

[0101] It should be noted that the electronic devices in the embodiments of this application include the mobile electronic devices and non-mobile electronic devices described above.

[0102] Figure 5 A schematic diagram of the hardware structure of an electronic device to implement an embodiment of this application. The electronic device 500 includes, but is not limited to, components such as: a radio frequency unit 501, a network module 502, an audio output unit 503, an input unit 504, a sensor 505, a display unit 506, a user input unit 507, an interface unit 508, a memory 509, and a processor 510. The input unit 504 may include an image processor 5041 and a microphone 5042; the display unit 506 may include a display panel 5061; and the user input unit 507 may include a touch panel 5071 and / or other input devices (such as a keyboard) 5072.

[0103] Those skilled in the art will understand that the electronic device 500 may also include a power supply (such as a battery) for supplying power to various components. The power supply may be logically connected to the processor 510 through a power management system, thereby enabling functions such as managing charging, discharging, and power consumption through the power management system. Figure 5 The electronic device structure shown does not constitute a limitation on the electronic device. The electronic device may include more or fewer components than shown, or combine certain components, or have different component arrangements, which will not be elaborated here. The memory 509 stores a program or instruction that can run on the processor. When the program or instruction is executed by the processor 510, it implements the various processes of the above-described embodiment of the parameter control method for ophthalmic optical devices and achieves the same technical effect. To avoid repetition, it will not be described again here.

[0104] This application also provides a readable storage medium storing a program or instructions. When the program or instructions are executed by a processor, they implement the various processes of the above-described ophthalmic optical device parameter control method embodiments and achieve the same technical effects. To avoid repetition, they will not be described again here.

[0105] The processor is the processor in the electronic device described in the above embodiments. The readable storage medium includes computer-readable storage media, such as computer read-only memory (ROM), random access memory (RAM), magnetic disk, or optical disk.

[0106] This application embodiment also provides a chip, which includes a processor and a communication interface. The communication interface is coupled to the processor. The processor is used to run programs or instructions to implement the various processes of the above-described embodiment of the parameter control method for ophthalmic optical devices, and can achieve the same technical effect. To avoid repetition, it will not be described again here.

[0107] It should be understood that the chip mentioned in the embodiments of this application may also be referred to as a system-on-a-chip, system chip, chip system, or system-on-a-chip, etc.

[0108] It should be noted that, in this document, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Without further limitations, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes that element. Furthermore, it should be noted that the scope of the methods and apparatuses in the embodiments of this application is not limited to performing functions in the order shown or discussed, but may also include performing functions substantially simultaneously or in the reverse order, depending on the functions involved. For example, the described methods may be performed in a different order than described, and various steps may be added, omitted, or combined. Additionally, features described with reference to certain examples may be combined in other examples.

[0109] Through the above description of the embodiments, those skilled in the art can clearly understand that the methods of the above embodiments can be implemented by means of software plus necessary general-purpose hardware platforms. Of course, they can also be implemented by hardware, but in many cases the former is a better implementation method. Based on this understanding, the technical solution of this application, in essence, or the part that contributes to the prior art, can be embodied in the form of a software product. This computer software product is stored in a storage medium (such as ROM / RAM, magnetic disk, optical disk) and includes several instructions to cause a terminal (which may be a mobile phone, computer, server, air conditioner, or network device, etc.) to execute the methods described in the various embodiments of this application.

[0110] The embodiments of this application have been described above with reference to the accompanying drawings. However, this application is not limited to the specific embodiments described above. The specific embodiments described above are merely illustrative and not restrictive. Those skilled in the art can make many other forms under the guidance of this application without departing from the spirit and scope of the claims, and all of these forms are within the protection scope of this application.

Claims

1. A parameter control method for ophthalmic optical equipment, characterized in that, include: Visual quality assessment or target risk assessment is performed on ocular data to obtain assessment results, wherein the target risks include presbyopia and AMD; Based on the assessment results, the target risk stage corresponding to the eye data is determined; Obtain multi-channel illumination parameters corresponding to the target risk stage, wherein the multi-channel illumination parameters are light source parameters of at least one channel used to improve post-refractive visual quality or reduce the target risk; The light source is controlled to output light through at least one channel according to the multi-channel illumination parameters.

2. The method according to claim 1, characterized in that, The assessment results include a visual quality score, and the at least one channel includes a corneal channel, a tear film channel, and a nerve regeneration channel; The determination of the target risk stage corresponding to the eye data based on the assessment results includes: The target risk phase is determined based on the visual quality score and the number of days after refractive surgery.

3. The method according to claim 2, characterized in that, The ocular data include uncorrected visual acuity, best corrected visual acuity, wavefront aberration, contrast sensitivity, tear film breakup time, and Schirmer test results; The visual quality assessment or target risk assessment of the eye data yields assessment results, including: The visual quality score is obtained by weighted summing of the uncorrected visual acuity, best corrected visual acuity, wavefront aberration, contrast sensitivity, tear film breakup time, and Schirmer test results.

4. The method according to claim 2, characterized in that, The target risk phases include: early healing phase, mid-term reshaping phase, and late optimization phase; The determination of the target risk phase based on the visual quality score and the number of days post-refractive surgery includes: If the number of days after refractive surgery is less than or equal to the first day threshold and the visual quality score is less than the first score threshold, the target risk stage is determined to be the early healing stage. If the number of days after refractive surgery is greater than the first day threshold and less than or equal to the second day threshold, and the visual quality score is less than the second score threshold, the target risk stage is determined to be the mid-term remodeling stage. If the number of days after refractive surgery is greater than the second day threshold and less than or equal to the third day threshold, the target risk stage is determined to be the late optimization stage; Wherein, the first score threshold is less than the second score threshold.

5. The method according to claim 4, characterized in that, The types of refractive surgery include LASIK, PRK, or SMILE; The threshold for the first day corresponding to PRK is greater than the threshold for the first day corresponding to LASIK and SMILE; The second day threshold corresponding to PRK is greater than the second day threshold corresponding to LASIK and SMILE; The third day threshold corresponding to PRK is greater than the third day threshold corresponding to LASIK and SMILE.

6. The method according to claim 2, characterized in that: The irradiation site of the corneal channel is the entire surface of the cornea, and the corneal channel uses 630-680nm red light; The irradiation location of the tear film channel is the meibomian gland region, and the tear film channel uses 630-680nm red light; The irradiation site of the nerve regeneration channel is the entire surface of the cornea, and the nerve regeneration channel uses 810-850nm near-infrared light.

7. The method according to claim 2, characterized in that, Also includes: During the process of controlling the light source to output light, corneal thickness, corneal temperature, and Scheimpflug image backscattering intensity are acquired; The corneal response index is determined based on the corneal thickness, corneal temperature, and Scheimpflug image backscattering intensity, and the multi-channel irradiation parameters are adjusted according to the corneal response index.

8. The method according to claim 7, characterized in that, The adjustment of the multi-channel irradiation parameters based on the corneal response index includes: When the corneal response index is greater than a first threshold, the power density in the multi-channel irradiation parameters is reduced by a first amount; when the corneal response index is less than a second threshold, the power density in the multi-channel irradiation parameters is increased by a second amount; the first threshold is greater than the second threshold.

9. The method according to claim 1, characterized in that, The assessment results include an AMD risk score and the severity of presbyopia; the at least one channel includes an AMD channel and a presbyopia channel; The determination of the target risk stage corresponding to the eye data based on the assessment results includes: The target risk stage is determined based on the AMD risk score and the severity of presbyopia. Obtaining multi-channel irradiation parameters corresponding to the target risk stage includes: Obtain the AMD channel irradiation parameters and presbyopia channel parameters corresponding to the target risk stage.

10. The method according to claim 9, characterized in that: For the AMD channel, the irradiation area includes the central 10-degree region of the macula, using 630-680nm red light with a power density of 8-25 mW / cm². For the presbyopia channel, the irradiation area includes the ciliary muscle ring area and the central area of ​​the lens, using 810-850nm near-infrared light with a power density of 15-30 mW / cm².

11. The method according to claim 9, characterized in that, The controlled light source outputs light through at least one channel according to the multi-channel illumination parameters, including: The light source is controlled to output illumination for the AMD channel according to the AMD channel illumination parameters, and after the illumination output for the AMD channel ends, the light source is controlled to output illumination for the presbyopia channel according to the presbyopia channel parameters.

12. The method according to claim 11, characterized in that, Also includes: During the illumination output of the AMD channel, an optical coherence tomography (OCT) image is acquired. When choroidal neovascularization is detected based on the OCT image, the illumination output of the AMD channel is stopped.

13. A parameter control device for ophthalmic optical equipment, characterized in that, include: The assessment module is used to perform visual quality assessment or target risk assessment on eye data to obtain assessment results. The target risks include presbyopia and AMD. The risk stage determination module is used to determine the target risk stage corresponding to the eye data based on the assessment results. The irradiation parameter acquisition module is used to acquire multi-channel irradiation parameters corresponding to the target risk stage. The multi-channel irradiation parameters are light source parameters of at least one channel used to improve postoperative visual quality or reduce target risk. The light source control module is used to control the light source to output light through at least one channel according to the multi-channel illumination parameters.

14. An electronic device, characterized in that, The device includes a processor, a memory, and a program or instructions stored in the memory and executable on the processor, wherein the program or instructions, when executed by the processor, implement the steps of the parameter control method for an ophthalmic optical device as described in any one of claims 1-12.

15. A readable storage medium, characterized in that, The readable storage medium stores a program or instructions that, when executed by a processor, implement the steps of the parameter control method for an ophthalmic optical device as described in any one of claims 1-12.